Concepedia

Author

Mariem Charafeddine

AbbVie (United States)

Also Known As

M Charafeddine, M. Charaf-Eddine, M. Charafeddine, Mariem Charafeddine, Mariem Charaf–Eddine

13

Publications

134

Citations

6

H-Index

15

Concepts

All Affiliations

AbbVie (United States)
MC

About

Mariem Charafeddine is an author at AbbVie (United States) specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

57

2

Public Health

1

1

30

3

Emergency Medicine

1

1

30

4

Global Health

1

1

30

5

Hepatology

1

1

27

Mariem Charafeddine

×

6

Publications

128

Citations

6

H-Index

YearCitations

Survival and Complications of Beta-Thalassemia in Lebanon

Khalil M. Charafeddine, Hussain Isma’eel, Mariem Charafeddine,

Acta Haematologica

2008

30

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials

Darshan Mehta, E. Cohen, Mariem Charafeddine,

Infectious Diseases and Therapy

2017

30

High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial)

Stéphane Chevaliez, Christophe Hézode, Alexandre Soulier,

Gastroenterology

2011

27

Efficacy and safety results of patients with <scp>HCV</scp> genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (<scp>QUARTZ II</scp>‐<scp>III</scp>)

Stephen D. Shafran, Douglas W. Shaw, Mariem Charafeddine,

Journal of Viral Hepatitis

2017

14

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Péter Ferenci, Stefan Bourgeois, Peter Buggisch,

Journal of Viral Hepatitis

2019

14

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

Fred Poordad, RuiSarmento E. Castro, Armen Asatryan,

Journal of Viral Hepatitis

2020

13

Page 1